anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Microvascular decompression (MVD) is the preferred treatment for hemifacial spasm (HFS) and trigeminal neuralgia (TN), and fully endoscopic microvascular decompression (E-MVD) has been widely discussed in recent years. Considering the endoscopic diving technique used in endoscopic transsphenoidal pituitary adenoma resection, we developed the endoscopic semidiving technique. This technique involves preserving some cerebrospinal fluid (CSF) and positioning the endoscope at an appropriate distance from it; the potential advantages include reducing cerebellar retraction, accurately identifying the responsible vessels and minimizing mechanical damage. This study aimed to preliminarily evaluate the safety and feasibility of the semidiving technique in E-MVD. A total of 359 patients with HFS and TN scheduled to undergo E-MVD were included in the study. Patients with each disease were divided into a nonsemidiving technique group and a semidiving technique group. Surgical data, postoperative outcomes, complications, and recurrence rates were compared between the groups. In patients with HFS, the effective rate was 95.6% (nonsemidiving)and 92.9% (semidiving) respectively, with no statistically significant difference. The semidiving technique group had a lower incidence of postoperative permanent hearing loss compared with the nonsemidiving technique group (0% vs. 5.9%). In TN patients, no significant differences in effectiveness or postoperative complications were observed. The application of the semidiving technique in E-MVD for HFS not only ensures surgical quality and postoperative efficacy but also reduces the incidence of postoperative hearing loss, shortens the surgical duration and reduces the number of postoperative hospitalization days, aligning with the concept of enhanced recovery after surgery (ERAS).
Patients who do not have an ideal response to antipsychotics treatment (reduction rate of Positive and Negative Symptom Scale (PANSS) score less than 25%) in sub-project 2 are recruited in this trial. They are randomly assigned to antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups, and the antipsychotic drugs used at this stage are still consistent with the first trial of sub-project 2. At baseline, 4 weeks and 8 weeks after treatment, all participants receive evaluations.
Mesenchymal stem cells (MSCs) have demonstrated considerable potential in tissue repair and the treatment of immune-related diseases, but there are problems with homing efficiency during MSCs transplantation. Exercise, as an intervention, has been shown to have an important impact on the properties of MSCs. This review summarizes the effects of exercise on the properties (including proliferation, apoptosis, differentiation, and homing) of bone marrow-derived MSCs and adipose-derived MSCs. Studies indicated that exercise enhances bone marrow-derived MSCs proliferation, osteogenic differentiation, and homing while reducing adipogenic differentiation. For adipose-derived MSCs, exercise enhances proliferation and reduces adipogenic differentiation. In addition, studies have investigated the therapeutic effects of combined therapy of MSCs transplantation with exercise on diseases of the bone, cardiac, and nervous systems. The combined therapy improves tissue repair by increasing the homing of transplanted MSCs and cytokine secretion (such as neurotrophin 4). Furthermore, MSCs transplantation also has potential for the treatment of obesity. Although the effect is not significant in weight loss, MSCs transplantation shows effects in controlling blood glucose, improving dyslipidemia, reducing inflammation, and improving liver disease. Finally, the potential role of combined MSCs transplantation and exercise therapy in addressing obesity is discussed.
PURPOSE: AI-assisted techniques for lesion registration and segmentation have the potential to make CT-based tumor follow-up assessment faster and less reader-dependent. However, empirical evidence on the advantages of AI-assisted volumetric segmentation for lymph node and soft tissue metastases in follow-up CT scans is lacking. The aim of this study was to assess the efficiency, quality, and inter-reader variability of an AI-assisted workflow for volumetric segmentation of lymph node and soft tissue metastases in follow-up CT scans. Three hypotheses were tested: (H1) Assessment time for follow-up lesion segmentation is reduced using an AI-assisted workflow. (H2) The quality of the AI-assisted segmentation is non-inferior to the quality of fully manual segmentation. (H3) The inter-reader variability of the resulting segmentations is reduced with AI assistance.
MATERIALS AND METHODS: The study retrospectively analyzed 126 lymph nodes and 135 soft tissue metastases from 55 patients with stage IV melanoma. Three radiologists from two institutions performed both AI-assisted and manual segmentation, and the results were statistically analyzed and compared to a manual segmentation reference standard.
RESULTS: AI-assisted segmentation reduced user interaction time significantly by 33% (222 s vs. 336 s), achieved similar Dice scores (0.80-0.84 vs. 0.81-0.82) and decreased inter-reader variability (median Dice 0.85-1.0 vs. 0.80-0.82; ICC 0.84 vs. 0.80), compared to manual segmentation.
CONCLUSION: The findings of this study support the use of AI-assisted registration and volumetric segmentation for lymph node and soft tissue metastases in follow-up CT scans. The AI-assisted workflow achieved significant time savings, similar segmentation quality, and reduced inter-reader variability compared to manual segmentation.
In 2022, an outbreak with severe bloodstream infections caused by Serratia marcescens occurred in an adult intensive care unit (ICU) in Hungary. Eight cases, five of whom died, were detected. Initial control measures could not stop the outbreak. We conducted a matched case-control study. In univariable analysis, the cases were more likely to be located around one sink in the ICU and had more medical procedures and medications than the controls, however, the multivariable analysis was not conclusive. Isolates from blood cultures of the cases and the ICU environment were closely related by whole genome sequencing and resistant or tolerant against the quaternary ammonium compound surface disinfectant used in the ICU. Thus, S. marcescens was able to survive in the environment despite regular cleaning and disinfection. The hospital replaced the disinfectant with another one, tightened the cleaning protocol and strengthened hand hygiene compliance among the healthcare workers. Together, these control measures have proved effective to prevent new cases. Our results highlight the importance of multidisciplinary outbreak investigations, including environmental sampling, molecular typing and testing for disinfectant resistance.
PURPOSE: An artificial nanofiber amnion membranes and a method of making the same are provided to obtain cure effect of burn or wound by using wider surface about a volume by the vertex of an electrospinning. CONSTITUTION: An ultrasonic wave is irradiated to an amnion under the pr0esence of 3-mercaptopropionic acid and acetic acid. The component of amnion is extracted. The extracted amnion component is dissolved like the collagen in solvent. The polyurethane is dissolved in solvent. A nano fiber is manufacture by co-spinning of the solution in which the polyurethanes is dissolved and the solution in which the amnion component and collagen are dissolved.
The present invention relates to a compound immune frog oil immune capsule and a preparation method thereof. Under the precondition of ensuring the immune effect, the preparation cost of the compound immune frog oil immune capsule is reduced. The compound immune frog oil immune capsule comprises the components by the weight compounding ratio: 5 to 15% of frog oil, 50 to 70% of frog bodies, 10 to 30% of lycium barbarum polysaccharide and 5 to 10% of tuckahoe. The preparation method comprises the steps: raw materials are conventionally detected and cleansed, and are in vacuum freeze drying; firstly, the raw materials are coarsely ground and supercritically extracted; then, the raw materials are in superfine grinding, and the raw materials are sieved by a sieve with 500 meshes; the four kinds of raw materials are compounded according to the component compounding ratio; the isotopic element sterilization, the detection, the bag filling operation, the polishing operation, the detection, the bottling operation, the packaging operation, the product detection and the qualified product identification are carried out. The compound immune frog oil immune capsule of the present invention can enhance human bodies' immunological competence. The preparation method has the advantages of simple equipment, low investment, easy operation and high rate of finished products.
PURPOSE:To obtain the titled substance, by administering or transplanting cancerous cells, etc. to an animal having no thymus, administering lymphocytic T cells or further B cells together thereto to give B cells capable of producing antibodies, fusing the resultant B cells with myelomatous cells, and cloning the fused cells. CONSTITUTION:10<3>-10<8> cancerous cells are administered to an animal, e.g. thymus deficient nude mouse, having no thymus, or the cancerous cells finely cut to 1-4mm. square are transplanted subcutaneously or intraperitoneally thereto, and multiplied. Lymphocytic T cells or further together with B cells are administered to the above-mentioned animal to produce B cells capable of producing antibodies. When the size of tumors is reduced to <=1/2 or vanished, the spleen is taken out of the animal, and subjected to cell fusion with myelomatous cells in the presence of a cell fusion agent, e.g. polyethylene glycol. The resultant fused cells are separated by the limiting dilution method, multiplied, and reacted with various cellular tissues by the fluorescent antibody method, etc. to select a hybridoma capable of producing the desired antibody.
Assessment of left ventricular \[LV\] or biventricular dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients identified as having biventricular dysfunction will be randomized within the LV dysfunction arm of the trial. Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
OBJECTIVES: I. Determine the feasibility of administering multiple courses of carboplatin and topotecan without excessive dose modification or course delay in patients with previously untreated ovarian epithelial or primary peritoneal carcinoma. II. Describe the response rate and progression-free interval in these patients with this treatment regimen. III. Determine pharmacokinetic and pharmacodynamic parameters related to the sequence of carboplatin and topotecan administration in these patients.

OUTLINE: Patients are assigned to one of three treatment regimens. Regimen I: Patients receive carboplatin IV over 30 minutes on day 1 followed by topotecan IV over 30 minutes on days 1-3. Treatment continues every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment continues every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Regimen II: Patients receive topotecan IV over 30 minutes on days 1-3 followed by carboplatin IV over 30 minutes on day 3. Treatment continues every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment continues every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Regimen III: Patients receive topotecan IV over 30 minutes on days 1-5 followed by carboplatin IV over 30 minutes on day 5. Treatment continues every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment continues every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 1 month and then every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 15-80 patients will be accrued for this study within 2 years.
A beverage syrup containing cannabinoids can be prepared by solubilizing insoluble cannabinoids in a diluent having dispersion surfactant properties. The diluent can be prepared by mixing a solvent having surfactant properties, such as polysorbate 80, with a co-surfactant, such as propylene glycol. Solid cannabinoids can solubilized by heating the solid concentrate to liquefying it, and then adding the liquid concentrate to the prepared diluent. The resulting syrup can be stored for use in the manufacture of beverages.A beverage syrup containing cannabinoids can be prepared by solubilizing insoluble cannabinoids in a diluent having dispersion surfactant properties. The diluent can be prepared by mixing a solvent having surfactant properties, such as polysorbate 80, with a co-surfactant, such as propylene glycol. Solid cannabinoids can solubilized by heating the solid concentrate to liquefying it, and then adding the liquid concentrate to the prepared diluent. The resulting syrup can be stored for use in the manufacture of beverages. Methods and compositions for enhancing an immune response, such as a mucosal immune response, to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites.
The invention relates to a process for preparing zirconia-based biocompatible ceramic materials, partially stabilized with other oxides at the room temperature, the so-obtained materials getting mechanical, thermal, chemical resistance and a special durability they being meant to be used in dental medicine for manufacturing porcelain implants. According to the invention, the process has the following stages: 1. the mixture, comprising the oxides or carbonates of the cations involved having the following compositions 5NaO. 10SiO. 70ZrO. 15YOand 0.5FeO. 5.5NaO. 6MgO. 8YO. 10SiO. 70ZrO, as mole percentage, is weighed with an analytical balance, 2. the mixture is ground in the preset stoichiometric compositions in an agate mortar, 3. the mixture is compacted as disks by uniaxial pressing, 4. the disks are introduced into alumina skillets in an electrical furnace heated to 1400°C and they are kept for 1...2 hours, 5. the disks are taken out of the furnace and placed on a stainless steel plate, and the X-ray analysis of the diffractograms indicates that, in their structure, the zirconia majority phase has a cubic/tetragonal configuration.
PROBLEM TO BE SOLVED: To obtain the subject new antigen polypeptide consisting of a polypeptide A containing a sequence of a specific number of amino acids present in a polypeptide having a specific amino acid sequence, stemmed from Chlamydia pneumoneae, and useful for e.g. diagnosing the infectious diseases due to the bacteria. SOLUTION: This new antigen polypeptide consists of a polypeptide A containing a sequence of a series of at least five amino acids present in a polypeptide of the formula and is involved with Chlamydia pneumoneae. This antigen polypeptide is inert to antibodies to such Chlamydia bacteria as Chlamydia trachomatis and Chlamydia psittaci but reactive only with a specific antibody to Chlamydia pneumoneae, therefore clan detect it, thus being useful for e.g. diagnosing Chlamydia pneumoneae-related infectious diseases. This new polypeptide is obtained by the following process: genome DNA is extracted from the elementary body of a Chlamydia pneumoneae YK-41 strain by conventional means, from which a DNA library is constructed and then screened, and the resultant gene coding for this polypeptide is manifested in host cells.
Subjects, 18 - 40 years, receiving two doses of placebo (saline solution) during Step 1 of the study and subjects, 50 - 70 years, receiving two doses of placebo (saline solution) during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
A vaccine capable of proucing T cell-dependent antibody to H. influenza type B polysaccharide is prepd. by mixing a C4-8 dicarboxylic acid (II) and hydrazide derivatised diphtheria or tetanus toxoid in cyanogen halide-free soln. with a cyanogen halide activated capsular H.  influenza B polysaccaride (III).  The conjugate (I) produced has a mol. wt. of 140,000-4,500,000 and a ribose/ protein ratio of 0.25-1.0.  (III) is previously sized by heating unitl over 60% is of mol. wt. 200,000-2,000,000 (dextran std., by gel permeation chromatog.) and comprises equimolar amts. of ribose, ribitol and phosphate.  (I) is esp. useful for prevention of Haemophilus infection in small children and also useful for immunisation against diphtheria and tetanus.
Benzylamine deriv. of formula (I) and its salts are made by (a) reaction of trans-4-acetoxy cyclohexylamine with 3,5-dibromo anthranilic acid chloride in anhydrous organic medium at ambient temp. and in presence of a tert. amine, e.g. triethylamine (b) treatment of the amide formed with hydrazine hydrate in alcoholic medium and (c) redn. of the prod. to the amine by a reducing agent e.g. diborane, at reflux temp.
We aim to determine the effects of dual antiplatelet therapy with aspirin 75mg once a day and clopidogrel 75mg once a day on platelet dependent thrombogenicity in patients with type 2 diabetes mellitus and acute coronary syndrome. Eighty patients (40 with type 2 diabetes and 40 without) have been studied one week after Non ST-elevation acute coronary syndrome. All patients were on secondary prevention therapy as recommended by international guidelines.
The clinical course of sickle cell disease (SCD) is very variable. Some patients experience vaso-occlusive disease infrequently, but other patients develop the complication recurrently. The reason for the difference remains unclear. Although erythrocyte sickling occurs due to factors such as dehydration, infections, extreme of temperatures, acidosis, and hypoxia, neutrophil adhesion and activation are crucial in eliciting the vaso-occlusive crisis in patients with SCD. Activated neutrophils upregulate the expression of various cellular adhesion molecules that increase their "stickiness" in vivo. A murine model of SCD demonstrated the importance of the intestinal microbiome in influencing the kinetics of ageing neutrophils. Depletion of the microbiota with prolonged courses of broad-spectrum systemic antibiotics resulted in a reduction of the number of these neutrophils and protection against LPS-induced fatal vaso-occlusive crisis in these mice.

Intestinal barrier is a functional barrier that separates the gut lumen from the inner host. It consists of mechanical elements (mucus, epithelial layer), humoral elements (defensins, IgA), immunologic elements (lymphocytes, innate immune cells), muscular and neurological element. Although the normal intestinal microbiota is the main source of endogenous pathogens, it also contributes to the functional integrity of the intestinal barrier through its interaction with the other components of the barrier. Failure of any of these components will result in a breakdown of the protective intestinal barrier with the consequence of recurrent intestinal-derived bacteremia/septicemia. A breakdown of the normal microbiome has been implicated in the development of various pathologic states, including Clostridium difficile infection, inflammatory bowel disease, intestinal graft-versus-host disease following allogeneic hematopoietic progenitor cell transplant, colon cancer, and metabolic disorders such as obesity and non-alcoholic steatohepatitis.

To explain the reason for the development of frequent vaso-occlusive crisis in some patients with SCD, the investigators' stepwise hypothesis is that, due to the sickling process and the consequent development of intestinal ischemia, patients with SCD, especially those with frequent vaso-occlusive crisis, are more likely to have altered microbiota than healthy individuals. If the normal microbiota is altered, the intestinal barrier will be compromised, rendering the patients more susceptible to recurrent bacteremia of intestinal origin. Since most SCD patients with vaso-occlusive crisis present without any obvious infections, it is likely that the compromised intestinal barrier facilitates an inoculum of bacteremia not high enough to cause overt infections but sufficient to activate neutrophils and elicit vaso-occlusive crisis. The first step towards testing this overall hypothesis is to test the sub-hypothesis that altered intestinal microbiomes correlate with increased number of activated neutrophils and frequent vaso-occlusive crisis in patients with SCD.
People who have never had a headache episode with migraine characteristics. These may present, at most, one episode per month of headache with non-migraine characteristics in the last 3 months. In turn, they should not have a family history of migraine (1st and 2nd degree).
Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. Its chemical name is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide and its structural formula is:

Structural Formula

C7H8CIN3O4S2 M.W. 297.74

Hydrochlorothiazide is a white, or practically white, crystalline powder, which is slightly soluble in water, but freely soluble in sodium hydroxide solution. 

Each tablet for oral administration contains 25 mg or 50 mg of hydrochlorothiazide USP. In addition, each tablet contains the following inactive ingredients: Anhydrous Lactose, Calcium Stearate, Corn Starch, Dibasic Calcium Phosphate, FD&C Yellow No. 6, FD&C Yellow No. 10, and Sodium Starch Glycolate.
1,177,400. Dobbies. STAUBLI & CO. GEB. 28 Sept., 1967 [7 Oct., 1966], No. 44212/67. Heading D1E. In a dobby as disclosed in Specification 1026389, in which pusher rails 12a, 12b operate baulks 9 carrying hooks 10a, 10b engageable by arrester hooks 18a, 18b, lost motion is provided between the arrester hooks and their tails 17a, 17b which are acted on by the pattern mechanism; the arrester hooks can therefore be positioned in the path of the hooks on the baulk before the pusher rails reach the end of their stroke, the lost motion allowing the hooks to snap into engagement under the action of springs 24a, 24b. As shown, the tails 17a, 17b are operated by pegs on opposite sides of the pattern chain 16. In another arrangement, the tail 17a points vertically downwards and the tail 17b points upwards, so that they are side-by-side and are operated by pegs on the same lag; alternatively, they may be operated by a paper pattern through pusher needles.
The Azūga™ in-vehicle driving feedback technology will be installed.32 This driving feedback technology consists of a pager-sized device plugged into the vehicle's on-board diagnostic (OBD) port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone). All feedback features will be disabled. Control dyads will receive no driving feedback. The parent will not receive STS. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.